A big win for patients and the first building block in what will be an improving toolbox for reducing death and disease from covid19. FDA's authorization allows for 5 day use in patients who aren't intubated, which will extend Gilead's supply of the drug. https://t.co/rkERVuSpJc

— Scott Gottlieb, MD (@ScottGottliebMD) May 1, 2020